Atherosclerotic cardiovascular disease remains a leading driver of global mortality, encompassing ischemic heart disease, peripheral vascular conditions, and ischemic stroke. Central to plaque development is the relentless transformation of vascular macrophages into lipid-laden foam cells. Recent breakthroughs demonstrate that mitochondrial dysfunction drives this pathological transition by disrupting cellular energy homeostasis and amplifying sterile inflammation. Consequently, applying mitochondrial omics in atherosclerosis provides unprecedented insight into the molecular networks governing macrophage behavior and lesion progression.

Macrophage Heterogeneity and the Foam Cell Cascade

Macrophages exhibit remarkable phenotypic plasticity within the atherosclerotic intima, adapting dynamically to localized hemodynamic stress and lipid overload. Initially, circulating monocytes extravasate into the subendothelial space in response to chemokine gradients. Once inside the arterial wall, these cells encounter modified lipoproteins, particularly oxidized low-density lipoprotein. The unregulated uptake of these atherogenic particles occurs primarily through scavenger receptors such as CD36 and SR-A1. When intracellular cholesterol influx exceeds esterification capacity and reverse cholesterol transport, lipid droplets accumulate rapidly within the cytoplasm. This persistent lipid accumulation prompts phenotypic polarization toward pro-atherogenic, inflammatory subtypes. Furthermore, single-cell profiling reveals distinct macrophage subsets within human plaques, ranging from inflammatory Trem2-expressing cells to necrotic core-associated populations. In this microenvironment, impaired efferocytosis accelerates secondary necrosis, releasing cytotoxic contents into the extracellular matrix. As a result, the expanding lipid core destabilizes the arterial architecture and heightens vulnerability to rupture. Understanding these phenotypic shifts provides vital context for targeting early cellular transformations before irreversible vascular damage occurs.

Advancing Mitochondrial Omics in Atherosclerosis

To dissect the intricate metabolic perturbations driving foam cell formation, researchers increasingly rely on high-resolution multi-omics profiling. Mitochondrial proteomics identifies alterations in respiratory chain complexes, chaperone networks, and structural proteins that maintain cristae integrity. Concurrently, interactomics delineates protein complexes that govern mitochondrial dynamics and transport. In addition, metabolomics and lipidomics characterize the remodeling of mitochondrial membrane phospholipids, acylcarnitines, and tricarboxylic acid intermediates. When investigators combine these platforms with stable isotope tracing, they can quantify real-time metabolic flux through glycolysis and oxidative phosphorylation. More recently, single-cell and spatial omics technologies have enabled spatial resolution of mitochondrial transcripts and proteins within specific plaque microenvironments. These integrative platforms demonstrate that lipid overload triggers a widespread downregulation of oxidative metabolism alongside an elevation in lipid peroxidation byproducts. Consequently, mitochondrial omics in atherosclerosis serves as a transformative analytical framework, illuminating novel regulatory nodes and potential biomarkers for vulnerable atherosclerotic plaques.

Mitochondrial Metabolic Reprogramming and Oxidative Stress

During the transition from quiescent macrophages to lipid-laden foam cells, cellular metabolism undergoes a profound metabolic switch. Under normal physiological conditions, macrophages maintain mitochondrial oxidative phosphorylation to generate efficient adenosine triphosphate. However, exposure to atherogenic lipoproteins promotes a shift toward aerobic glycolysis, mirroring the classic Warburg effect seen in activated inflammatory cells. This metabolic reprogramming compromises mitochondrial membrane potential and diminishes electron transport chain efficiency. Consequently, the leakage of electrons from complexes I and III increases, driving excessive mitochondrial reactive oxygen species production. Elevated mitochondrial superoxide subsequently oxidizes adjacent macromolecules, damaging mitochondrial DNA and propagating lipid peroxidation. Furthermore, mitochondrial oxidative stress activates downstream transcriptional pathways, including STAT5 and nuclear factor kappa B signaling. These transcription factors stimulate the sustained secretion of pro-inflammatory cytokines, including interleukin-1 beta and tumor necrosis factor alpha. Therefore, mitochondrial oxidative stress acts not merely as a consequence of lipid ingestion, but as a proactive regulator of sustained vascular inflammation.

Organelle Crosstalk and Lipotoxicity in Lesion Vulnerability

Mitochondria do not function in isolation; rather, they engage in continuous physical and biochemical crosstalk with adjacent intracellular organelles. Within the foam cell, excess intracellular cholesterol disrupts the structural integrity of mitochondria-associated endoplasmic reticulum membranes. This structural disruption alters calcium signaling kinetics between the endoplasmic reticulum and the mitochondrial matrix. Consequently, mitochondrial calcium overload opens the mitochondrial permeability transition pore, triggering cytochrome c release and caspase activation. In parallel, impaired mitochondrial fatty acid oxidation fosters the accumulation of toxic lipid intermediates, such as ceramides and diacylglycerols. These bioactive lipids induce severe endoplasmic reticulum stress and activate the unfolded protein response. Additionally, defective mitophagy prevents the efficient clearance of damaged mitochondria, thereby aggravating cytosolic accumulation of fragmented mitochondrial DNA. When released into the cytosol, fragmented mitochondrial DNA activates cyclic GMP-AMP synthase and the NLRP3 inflammasome. This persistent organelle crosstalk drives apoptotic signaling, foam cell death, and necrotic core expansion.

Therapeutic Targeting of Mitochondrial Dysfunction

Given the pivotal contribution of mitochondrial impairment to plaque vulnerability, restoring mitochondrial homeostasis represents an attractive cardiovascular therapeutic strategy. Investigators are evaluating several pharmacological agents designed to quench mitochondrial oxidative stress and enhance metabolic efficiency. Specifically, mitochondria-targeted antioxidants, such as MitoQ and Szeto-Schiller peptides, concentrate within the inner mitochondrial membrane to neutralize reactive oxygen species directly. In addition, small-molecule activators of peroxisome proliferator-activated receptor gamma coactivator 1-alpha stimulate mitochondrial biogenesis, thereby restoring oxidative phosphorylation capacity. Pharmacological induction of mitophagy using specialized autophagy modulators also facilitates the selective removal of dysfunctional mitochondria, which attenuates inflammasome activation. Furthermore, targeting metabolic checkpoints, such as pyruvate dehydrogenase kinase and fatty acid oxidation enzymes, helps rebalance macrophage immunometabolism. Clinical translation of these targeted strategies may stabilize high-risk plaques and curb ischemic cardiovascular events in high-risk patient populations.

Future Perspectives for Clinical Cardiology and Pathology

Translating insights from mitochondrial omics into routine clinical cardiology requires ongoing cross-disciplinary collaboration among pathologists, biochemists, and clinicians. Currently, traditional cardiovascular risk stratification depends primarily on circulating systemic biomarkers, lipid panels, and conventional imaging modalities. However, these tools often fail to capture active cellular inflammation and metabolic instability within individual coronary plaques. In the near future, identifying circulating mitochondrial biomarkers, such as cell-free mitochondrial DNA and specific acylcarnitine signatures, could facilitate non-invasive detection of unstable lesions. Furthermore, integrating spatial mitochondrial multi-omics with high-resolution intravascular imaging could enable precise localization of vulnerable plaque phenotypes. Clinicians could subsequently tailor aggressive anti-inflammatory and lipid-lowering regimens to individual plaque biology. Ultimately, leveraging mitochondrial omics will advance precision vascular medicine, transforming how clinicians diagnose, monitor, and treat atherosclerotic cardiovascular disease.

Frequently Asked Questions

How does mitochondrial dysfunction accelerate macrophage foam cell formation?

Mitochondrial dysfunction impairs fatty acid oxidation and cellular energy production in macrophages exposed to oxidized lipids. Consequently, the macrophage fails to metabolize internalized cholesterol, promoting intracellular lipid droplet accumulation. Furthermore, excessive mitochondrial reactive oxygen species trigger inflammatory signaling pathways and impair reverse cholesterol transport mechanisms, accelerating the phenotypic transformation into atherogenic foam cells.

What unique analytical advantages do mitochondrial omics provide in atherosclerosis research?

Mitochondrial omics platforms integrate high-resolution proteomics, metabolomics, lipidomics, and isotope tracing to comprehensively map organellar molecular changes. These techniques identify precise alterations in respiratory chain subunits, lipid intermediate accumulation, and energetic pathway remodeling within plaque macrophages. Thus, mitochondrial omics pinpoints mechanistic vulnerabilities and novel therapeutic targets that traditional whole-cell assays cannot capture.

Can mitochondrial-targeted therapies improve atherosclerotic plaque stability in clinical settings?

Preclinical studies demonstrate that mitochondria-targeted antioxidants and mitophagy enhancers reduce plaque inflammation and limit necrotic core expansion. By neutralizing mitochondrial reactive oxygen species and clearing damaged organelles, these therapies prevent macrophage apoptosis and preserve fibrous cap thickness. Ongoing translational research aims to establish their clinical efficacy alongside standard lipid-lowering and anti-inflammatory therapies.

Disclaimer: This content is for informational and educational purposes only and should not be considered medical advice. It is not intended to replace consultation with a qualified healthcare professional. While we strive to provide accurate and up-to-date information, medical knowledge is constantly evolving, and individual circumstances may vary. Healthcare providers must exercise their independent clinical judgment when diagnosing and treating patients. Readers are encouraged to verify information and seek professional medical advice as appropriate. Refer to the latest local and national guidelines for clinical practice.

References

1. Wu E et al. Mitochondrial Omics in Macrophage Foam Cell Formation and Atherosclerosis. Proteomics. 2026 Aug 15. doi: 10.1002/pmic.70172. PMID: 42603168.
2. Libby P. The changing landscape of atherosclerosis. Nature. 2021;592(7855):524-533.
3. Chistiakov DA, Melnichenko AA, Myasoedova VA, Grechko AV, Orekhov AN. Mechanisms of foam cell formation in atherosclerosis. J Mol Med (Berl). 2017;95(11):1153-1165.
4. Peng FJ, Shen L, Zhou X, et al. Mitochondrial ROS drive foam cell formation via STAT5 signaling in atherosclerosis. Nat Commun. 2025;16(1):7432.